Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of CYD-TDV (Dengvaxia) in Asian Children
NCT01373281Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2011
- Primary completion
- Aug 2014
- Modality
- Live Attenuated Vaccines, Recombinant Vaccines
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of Cyd dengue virus serotype 1 live (attenuated) antigen in dengue fever (2 arms), sponsored by Sanofi. Primary endpoint: Number of Symptomatic Virologically Confirmed Dengue (VCD) Cases Due to Any Serotype During the Active Phase Post-dose 3. Started Jun 2011; status: completed.
02
Drugs
Cyd dengue virus serotype 1 live (attenuated) antigen
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT01373281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01373281.